Commodore Capital Lp - Net Worth and Insider Trading

Commodore Capital Lp Net Worth

The estimated net worth of Commodore Capital Lp is at least $224 Million dollars as of 2024-12-27. Commodore Capital Lp is the 10% Owner of Vera Therapeutics Inc and owns about 4,400,000 shares of Vera Therapeutics Inc (VERA) stock worth over $187 Million. Commodore Capital Lp is the 10% Owner of Enliven Therapeutics Inc and owns about 1,448,640 shares of Enliven Therapeutics Inc (ELVN) stock worth over $33 Million. Commodore Capital Lp is also the 10% Owner of Vistagen Therapeutics Inc and owns about 1,575,000 shares of Vistagen Therapeutics Inc (VTGN) stock worth over $4 Million. Besides these, Commodore Capital Lp also holds Satsuma Pharmaceuticals Inc (STSA) . Details can be seen in Commodore Capital Lp's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Commodore Capital Lp has not made any transactions after 2024-01-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Commodore Capital Lp

To

Commodore Capital Lp Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Commodore Capital Lp owns 5 companies in total, including Satsuma Pharmaceuticals Inc (STSA) , Enliven Therapeutics Inc (ELVN) , and Ambrx Biopharma Inc (AMAM) among others .

Click here to see the complete history of Commodore Capital Lp’s form 4 insider trades.

Insider Ownership Summary of Commodore Capital Lp

Ticker Comapny Transaction Date Type of Owner
STSA Satsuma Pharmaceuticals Inc 2022-11-14 10 percent owner
ELVN Enliven Therapeutics Inc 2023-02-23 10 percent owner
AMAM Ambrx Biopharma Inc 2023-02-23 10 percent owner
LIMIT LIMIT 2024-01-10 10 percent owner
LIMIT LIMIT 2023-08-07 10 percent owner

Commodore Capital Lp Latest Holdings Summary

Commodore Capital Lp currently owns a total of 4 stocks. Among these stocks, Commodore Capital Lp owns 4,400,000 shares of Vera Therapeutics Inc (VERA) as of January 10, 2024, with a value of $187 Million and a weighting of 83.28%. Commodore Capital Lp owns 1,448,640 shares of Enliven Therapeutics Inc (ELVN) as of February 23, 2023, with a value of $33 Million and a weighting of 14.67%. Commodore Capital Lp also owns 1,575,000 shares of Vistagen Therapeutics Inc (VTGN) as of August 7, 2023, with a value of $4 Million and a weighting of 1.83%. The other 1 stocks Satsuma Pharmaceuticals Inc (STSA) have a combined weighting of 0.23% among all his current holdings.

Latest Holdings of Commodore Capital Lp

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VERA Vera Therapeutics Inc 2024-01-10 4,400,000 42.45 186,780,000
ELVN Enliven Therapeutics Inc 2023-02-23 1,448,640 22.71 32,898,614
VTGN Vistagen Therapeutics Inc 2023-08-07 1,575,000 2.60 4,095,000
STSA Satsuma Pharmaceuticals Inc 2022-11-14 461,286 1.10 507,415

Holding Weightings of Commodore Capital Lp


Commodore Capital Lp Form 4 Trading Tracker

According to the SEC Form 4 filings, Commodore Capital Lp has made a total of 2 transactions in Vera Therapeutics Inc (VERA) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Vera Therapeutics Inc is the sale of 1,050,000 shares on January 10, 2024, which brought Commodore Capital Lp around $19 Million.

According to the SEC Form 4 filings, Commodore Capital Lp has made a total of 1 transactions in Enliven Therapeutics Inc (ELVN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Enliven Therapeutics Inc is the acquisition of 622 shares on February 23, 2023, which cost Commodore Capital Lp around $13,722.

According to the SEC Form 4 filings, Commodore Capital Lp has made a total of 1 transactions in Vistagen Therapeutics Inc (VTGN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Vistagen Therapeutics Inc is the acquisition of 775,756 shares on August 7, 2023, which cost Commodore Capital Lp around $18 Million.

More details on Commodore Capital Lp's insider transactions can be found in the Insider Trading History of Commodore Capital Lp table.

Insider Trading History of Commodore Capital Lp

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Commodore Capital Lp Trading Performance

GuruFocus tracks the stock performance after each of Commodore Capital Lp's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Commodore Capital Lp is -16.22%. GuruFocus also compares Commodore Capital Lp's trading performance to market benchmark return within the same time period. The performance of stocks bought by Commodore Capital Lp within 3 months outperforms 1 times out of 13 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Commodore Capital Lp's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Commodore Capital Lp

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 13 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -13.6 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -14.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Commodore Capital Lp Ownership Network

Ownership Network List of Commodore Capital Lp

No Data

Ownership Network Relation of Commodore Capital Lp

Insider Network Chart

Commodore Capital Lp Owned Company Details

What does Satsuma Pharmaceuticals Inc do?

Who are the key executives at Satsuma Pharmaceuticals Inc?

Commodore Capital Lp is the 10 percent owner of Satsuma Pharmaceuticals Inc. Other key executives at Satsuma Pharmaceuticals Inc include 10 percent owner Shin Nippon Biomedical Laboratories, Ltd. , director & 10 percent owner Ken Takanashi , and 10 percent owner Braden Michael Leonard .

Satsuma Pharmaceuticals Inc (STSA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Satsuma Pharmaceuticals Inc (STSA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Satsuma Pharmaceuticals Inc (STSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Satsuma Pharmaceuticals Inc (STSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Satsuma Pharmaceuticals Inc Insider Transactions

No Available Data

Commodore Capital Lp Mailing Address

Above is the net worth, insider trading, and ownership report for Commodore Capital Lp. You might contact Commodore Capital Lp via mailing address: 444 Madison Avenue, 35th Floor, New York Ny 10022.

Discussions on Commodore Capital Lp

No discussions yet.